Search results

The World Council of Churches - Ecumenical Advocacy Alliance endorses a newly expanded collaboration on HIV between the Medicine Patent Pool and Gilead. On 4 October, the MPP announced a licence with Gilead Sciences for bictegravir, a new integrase inhibitor part of a once-daily, single-tablet HIV regimen currently filed for regulatory approval at the United States Food and Drug Administration and the European Union.

The World Council of Churches - Ecumenical Advocacy Alliance applauds the first licensing agreement related to tuberculosis, announced on 25 January by the Medicines Patent Pool and Johns Hopkins University. The agreement will facilitate the clinical development of sutezolid, a tuberculosis drug candidate. The antibiotic sutezolid, in combination with other drugs, could be used to more effectively treat drug-sensitive and drug-resistant tuberculosis.

To help the world’s children become HIV-free, faith groups must help bring UN goals to life through strong advocacy, rapid action and unprecedented collaboration, say experts. Children must be helped onto a “Super Fast Track” to end AIDS or they will die at what Dr Stuart Kean describes as a “shocking” rate.

People of faith and representatives of faith-based organizations demonstrated their commitment to meet the “Fast Track” challenges to end the AIDS epidemic at the 21st International AIDS Conference in Durban, 18-22 July. Extensive coverage of faith-based participation is available via www.iacfaith.org. Articles, video and photos will continue to be added.

As a United Nations high-level meeting on ending AIDS led to the adoption of a new political declaration to fast-track progress toward combating HIV and AIDS, the faith community responded, both with words of commendation and a call for changes.

The World Council of Churches – Ecumenical Advocacy Alliance (WCC-EAA) welcomes the 25 April announcement by the Medicines Patent Pool (MPP) and ViiV Healthcare of the geographic extension of their licensing agreement for dolutegravir (DTG) to cover all remaining lower middle-income countries (LMICs). The amendment to the 2014 licence specifically allows generic medicine distribution in four countries with patents – Armenia, Moldova, Morocco and Ukraine – that were not covered in the initial agreement. Dolutegravir is a promising new treatment that was included in the latest WHO guidelines as first- and third-line treatment.

Faith-based organizations presented significant input at a 6 April United Nations civil society hearing in New York City, a prelude to a UN High Level Meeting on HIV in New York on 8-10 June.